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SYNTHESIS AND CYTOTOXICITY OF AZAHETEROCYCLIC COMPOUNDS 
2017-2018 
Subash Jonnalagadda, Ph.D. 
Master of Science in Pharmaceutical Sciences 
 
Multicomponent coupling reactions (MCRs) have been known for a long time and 
one such reaction that utilizes isocyanides is Passerini reaction. It is a powerful tool to 
synthesize libraries of different compounds. Azaheterocyclic compounds play an important 
role in medicinal chemistry. Motifs such as imidazoles, piperazines, pyrazoles, pyridines, 
triazoles, etc. are routinely observed in several compounds of pharmacological interest. 
Several natural products also contain these motifs in them. We have undertaken a library 
synthesis of heterocyclic molecules driven by our group’s long-standing interest of 
synthesizing medicinally relevant small molecules employing green chemistry techniques.  
This thesis details our efforts on the development of novel synthetic methodologies 
for the synthesis of functionalized azaheterocyclic compounds as potential anti-cancer 
agents. We initiated the synthesis of these compounds employing Passerini reaction as the 
key step. The biological evaluation of these synthetic derivatives showed some promise as 
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Multicomponent Coupling Reactions 
  The arrangement of specific sets of complicated molecules can be easily 
accomplished by utilizing diversity-oriented synthesis. A multi-component reaction 
(MCR) merges three or more structural motifs into one unique compound. With a limited 
number of reaction steps, MCRs provide easy access to large libraries of organic 
compounds with diverse functionalization.  
History of Multicomponent Chemistry 
 The approach of MCR is not obscure in nature and it appears that adenine 1, one of 
the key components of DNA and RNA, was prebiotically assembled by the arrangement of 
five fragments of hydrogen cyanide, in a process facilitated by ammonia under prebiotic 
pressure conditions (Figure 1). The additional nucleic bases have also been created under 
similar conditions involving HCN and water.1 
 
 
Figure 1. Probiotic synthesis of adenine 
 
 Strecker’s synthesis of α-amino nitriles 3 is one of the first examples of 











hydrogen cyanide and ammonia to generate α-amino nitriles 3, which were further 
hydrolyzed to provide easy access to α-amino acids 4 (Figure 2). 
 
 
Figure 2. Strecker synthesis of α-aminoacids 
 
 Hantzsch described the synthesis of symmetrical dihydropyridines 6 by reacting 
aldehydes 2 with 2 moles of β-ketoesters 5 in the presence of ammonia (Figure 3).3   
Hantzsch also demonstrated the synthesis of pyrroles 9 by combining primary amines 7 
with β-ketoesters 5, and α-halogenated β-ketoesters 8.4 
 
Figure 3. Hantzsch dihydropyridine synthesis 
 
 




















 The Biginelli reaction first explained in 1893 is a multicomponent synthesis of 
dihydropyrimidines 13 via acid-catalyzed cyclocondensation of β-keto esters 10, aromatic 
aldehydes 11, and urea 12 (Figure 5).5  
 
Figure 5. Biginelli synthesis of dihydropyrimidines 
 Sir Robert Robinson showed the first prominent use of MCRs in natural product 
chemistry via the synthesis of the alkaloid tropinone 18 starting from succinic dialdehyde 
14, methylamine 15, and calcium salt of acetone dicarboxylic acid 16 (Figure 6).6  
 
 
Figure 6. Robinson synthesis of tropinone 
 Passerini discovered the first MCR reaction involving isocyanides in 1921. In this 
reaction, carboxylic acids, carbonyl compounds, and isocyanides react with each other in 
a one-step transformation afforeding α-acyloxy carboxamides 22 (Figure 7).7-10 While 
there have been multiple mechanisms proposed for this reaction, the most commonly 


















Figure 7. Passerini multicomponent coupling reaction 
 
 Bucherer and Bergs outlined a four-component coupling reaction in 1934 for the 
synthesis of hydantoins via a one-pot reaction of aldehyde 2 with HCN, NH3 and CO2.  
Hydantoins could be efficiently converted into α-amino acids through simple hydrolysis 
(Figure 8).12  
 
Figure 8. Bucherer-Bergs synthesis of hydantoin 
 
 Another illustration of MCR is the Asinger reaction disclosed in 1958. In this 
reaction, α-thiolocarbonyl compounds 25 when treated with ketones 24 in the presence of 
ammonia yielded thiazolines 26 (Figure 9).13  
 
 




 In 1959, Ugi et al. expanded the utility of Passerini reaction for the synthesis of α-
acylamino amides 28 via the treatment of aldehydes 2 with primary amines 27, carboxylic 
acids 19, and isocyanides 21 (Figure 10).14  
 
Figure 10. Ugi four component coupling reaction 
 
 Gewald et al. reported the synthesis of polysubstituted thiophenes 31 via the 
reaction of ketones 29 with active methylene compounds 30 in the presence of sulfur and 





Figure 11. Gewald’s reaction 
Synthesis of Isocyanides 
 For a long time, isocyanides (isonitriles) have been described as a rare class of 




smell, accordingly isocyanides have been examined as promising non-fatal weapons.16  
There have been several methods of synthesis reported for isocyanides.17  
 One of the first methods reported for the preparation of isocyanides 33 involves the 
reaction of silver cyanide with allyl iodide 32 (Figure 12).18,19 The unpleasant odor 
associated with this reaction can be minimized via an in situ preparation of isocyanide, by 
reacting the corresponding bromides with silver and potassium cyanide in acetonitrile at 




Figure 12. Lieke synthesis of isocyanides 
 
 Hofmann reported the synthesis of isocyanides 38 via condensation of the primary 
amine 36 with a dichlorocarbene 35, produced in situ by heating chloroform 34 with 
potassium hydroxide (Figure 13).21 However, this method suffers from the lack of 
reproducibility, small yield, and problems associated with the separation of isocyanides 
from amines.  Ugi further upgraded this method by performing it in a biphasic medium - 






             Figure 13. Hoffmann synthesis of isocyanides 
 
 Ugi also discovered a method for the formation of isocyanides using dehydration 
of N-monosubstituted formamides 40, which in turn could be obtained from primary 
amines 36 and alkyl formate/formic acid 39 (Figure 14).23  Miscellaneous dehydrating 
agents such as thionyl chloride, phosphorus tribromide, phosphorus pentoxide, phosphorus 
oxychloride, and oxalyl chloride have been employed in the presence of a base like 






Figure 14. Synthesis of isocyanides via dehydration of formamide 
 
 Trifluoromethyl isocyanide 44 was synthesized via the treatment of magnesium 




Figure 15. Synthesis of isocyanides from geminal dihalides 
 Another method for the preparation of isocyanides 48 involves the trapping of 
organolithium derivatives of oxazoles and benzoxazoles 45 with eletrophiles such as acid 





Figure 16. Synthesis of isocyanides from benzoxazole 
Heterocyclic Motifs 
 In our present work we utilized chloroquinoline, chloropyridine, and pyrazole 
heterocyclic motifs for the diverse functionalization utilizing Passerini reaction. Quinoline 
moiety is the key building element in many naturally occurring compounds27-28 and 
pharmacologically active substances.29-32 Quinoline containing compounds are known to 
exhibit wide variety of biological activities such as anti-tuberculosis,33 anti-malarial,34 anti-
bacterial,35 anti-fungal,36 anti-protozoic, antibiotic,37 and anti-asthma.38 Several quinolones 









Figure 17. Quinoline-based antimalarial drugs39 
 
 Pyridine based compounds have also been widely utilized as drugs. Niflumic acid 
55 is an analgesic and anti-inflammatory medication used for rheumatoid arthritis. 
Sulfapyridine 56 is used as antibacterial drug40. Mepyramine 58, also known as pyrilamine 
is the first-generation antihistaminic drug.41-43 Pinacidil 59 is a cyanoguanidine drug used 
for treating the symptoms of multiple sclerosis.44 Picoxicam 60 is a nonsteroidal anti-












































Figure 18. Pyridine-based drugs 
 
 Piperonal (heliotropin) is an aromatic aldehyde found in many essential oils,45 
vanilla and camphor46,47 and has been shown to have antibacterial48 and anxiolytic 
activities. Additionally, few piperonal derivatives display a promising anticancer activity,49 
antileishmanial effect50 and other pharmacological activities.51,52  
 Pyrazoles play a significant role in natural product and medicinal chemistry. Knorr 
discovered the antipyretic action of pyrazole derivatives and named the compound 
antipyrine.53 Kosuge and Okeda isolated 3-n-nonylpyrazole 61 from Houttuynia Cordata, 
a plant of the piperaceae group from tropical Asia, which displayed antimicrobial activity. 














































Figure 19. Pyrazole-based natural products 
 
 The pyrazole ring system is present in an array of drugs such as Celecoxib,55 
Ionazolac,56 Pyrazofurin,57 Fezolamin,58 Rimonabant,59 Ruxolitinib,60 Crizotinib,61 
Tepoxalin62 etc. (Figure 20).63-65 Pyrazoles also play a role in agrochemicals and as 






















Azaheterocyclic Compounds via Passerini Reaction 
Preparation of Chloroquinoline Conjugates 
 We undertook the synthesis of azaheterocyclic compounds via Passerini reaction 
and the synthetic scheme is shown in Figure 21.  The synthesis was initiated via a three-
component coupling between p-bromomethylbenzoic acid 72, chloroquinoline aldehyde 
73, and t-butylisocyanide.  The resulting bromomethylbenzoate 74 was further treated with 
a variety of secondary amines to produce the target compounds 75 (Figure 21). 
 
 
Figure 21. Preparation of chloroquinoline conjugates 
 p-Bromomethyl benzoic acid 72 was synthesized in 90% yield starting from p-
toluic acid 76 using potassium bromate and sodium thiosulfate at room temperature via 
benzylic halogenation (Figure 22).67 The compound 72 was confirmed by 1H-NMR 






Figure 22. Preparation of p-bromomethylbenzoic acid 
 
 2-Chloroquinoline aldehyde 73 was synthesized from acetanilide 77 under 
Vilsmeier-Haack reaction conditions involving POCl3 and DMF at 80
oC in 89% yield.68 




Figure 23. Preparation of 2-chloroquinoline aldehyde 
 
  p-Bromobenzoic acid 72 was subsequently reacted with chloroquinoline aldehyde 
73 and t-butyl isocyanide in presence of a protic solvent (water) and stirred at room 






Figure 24. Passerini reaction with 2-chloroquinoline aldehyde 
  The benzylic bromide in 74 was substituted with morpholine 78a in the presence 
of DMF and K2CO3 to yield the final target compound 75a (Figure 25). The reaction was 
carried out at room temperature for 24 hours and the product was obtained in 90% yield. 
 
 
Figure 25. Preparation of 2-chloroquinoline-morpholine conjugate 
 After standardizing the above substitution, the bromide 74 was further treated with 
variety of amines such as N-methylpiperazine, imidazole, 4-aminopiperidine, triazole, 
pyrrolidine, 2-ethylimidazole, 2-methyl-5-methylimidazole, 4-nitroimidazole, and N-
butoxycarbonylpiperazine to yield the target amine compounds 75b-j respectively (Figures 
26 and 27).  All the synthesized compounds were tested for their biological activity against 
three cancer cell lines SK-MEL (melanoma), MCF-7 and MDA-MB-231 (breast cancer) 

























































































Table 1  
In Vitro Cytotoxicity of 2-Chloroquinoline Derivatives. 




Cytotoxicity (IC50 µM) CLogP 
SKMEL5  MCF-7  MDA-
MB-231  
 
1. 74 96 142-143 >20 >20 >20 5.2202 
2. 75a 55 119-120 >20 >20 >20 4.1852 
3. 75b 89 140-145 >20 >20 >20 4.7462 
4. 75c 51 113-116 19.0 >20 >20 3.4782 
5. 75d 51 98-99 >20 >20 >20 3.8012 
6. 75e 70 104-106 >20 >20 >20 3.5113 
7. 75f 68 103-108 >20 >20 >20 4.9062 
8. 75g 82 109-111 >20 >20 14.55 4.5992 
10. 75h 87 143-144 >20 >20 >20 4.1873 
9. 75i 88 130-131 >20 >20 >20 3.6783 
11. 75j 89 105-107 >20 >20 >20 6.1582 
 
 
Preparation of Piperonal Conjugates 
 We then shifted our focus toward the synthesis of piperonal based Passerini adduct 
80.  The reaction of p-bromomethylbenzoic acid 72 with piperonal 79 and t-
butylisocyanide yielded the benzylic bromide 80, which was further treated with variety of 
secondary amines to yield the target amine compounds 81a-e (Figures 28 and 29).  All the 
synthesized compounds were tested for their biological activity against three cancer cell 
lines SK-MEL (melanoma), MCF-7 and MDA-MB-231 (breast cancer) (Table 2).  None 























































Table 2  
In Vitro Cytotoxicity of Piperonal Derivatives. 




Cytotoxicity (IC50 µM) CLogP 
SKMEL5  MCF-7  MDA-
MB-231  
 
1. 80 98 153-155 >20 >20 >20 4.5012 
2. 81a 92 178-180 >20 >20 >20 3.4662 
3. 81b 78 92-93 >20 >20 >20 4.0272 
4. 81c 67 83-84 >20 >20 >20 3.0822 
5. 81d 54 92-94 >20 >20 ~20 2.7592 
6. 81e 50 120-121 >20 >20 >20 2.7923 
 
 
Preparation of Chloropyridine Conjugates 
 Finally, we synthesized the chloropyridine based Passerini adducts 83 and 84.  The 
reaction of p-bromomethylbenzoic acid 72 with chloropyridine aldehyde 82 and t-
butylisocyanide yielded the benzylic bromide 83, which was further treated with variety of 
secondary amines to yield the target amine compounds 84a-e (Figures 30 and 31).  All the 
synthesized compounds were tested for their biological activity against three cancer cell 
lines SK-MEL (melanoma), MCF-7 and MDA-MB-231 (breast cancer) (Table 3).  Most of 
these compounds did not show significant cytotoxicity at ~20 M concentration. The 
benzylic bromide 83 exhibited toxicity against SK-MEL and MDA-MB-231 cell lines with 
























































Table 3  
In Vitro Cytotoxicity of 2-Chloropyridine Derivatives. 




Cytotoxicity (IC50 µM) CLogP 
SKMEL5  MCF-7  MDA-
MB-231  
 
1. 83 92 128-129 4.05 16.16 6.39 3.8362 
2. 84a 80 78-80 >20 >20 >20 2.8012 
3. 84b 71 99-100 >20 >20 >20 3.3622 
4. 84c 77 103-104 >20 >20 >20 2.4172 
5. 84d 59 113-115 >20 >20 >20 2.0942 
6. 84e 76 95-97 >20 >20 >20 2.1273 
 
 
 In an effort to increase the solubility and efficacy of the target compounds, the N-
methylpiperazine adducts 75b, 81b, and 84b were converted to the corresponding 
quaternary ammonium salts 85-87 respectively upon treatment with methyl iodide in 





Figure 32. Preparation of quaternary ammonium salts  
 
Preparation of Pyrazole Conjugates 
 The outline for the synthesis of pyrazole based Passerini adducts is shown in Figure 
33.  The synthesis was initiated with the condenstaion of acetophenone 88 with phenyl 
hydrazine 89 to yield the hydrazone 90.  Hydrazone 90  upon Vilsmeier-Haack formylation 
yielded the aldehyde 91 which upon oxidation with KMnO4 furnished the carboxylic acid 
92.  The reaction of acid 92 with benzaldehyde 93 benzyl isocyanide 94 resulted in the 





Figure 33. Preparation of pyrazole derivatives 
 
 Hydrazine hydrochloride 89 and acetophenone 88 were refluxed in anhydrous 
ethanol in the presence of catalytic acetic acid for 7 hours and the completion of reaction 
was monitored by TLC using10% EtOAc/Hexane. The reaction mixture was cooled to 
room temperature, when the product precipitated out of the reaction mixture. The product 
was filtered, washed with cold ethanol and dried under vaccum to obtaine pure 




































Figure 34. Preparation of phenylhydrazone 
 
 Phosphoryl chloride was added to DMF and the mixture stirred for 1hr at 0⁰C. The 
mixture was then slowly added to a solution of acetophenone phenylhydrazone 90 in DMF 
and the reaction mixture was allowed to stir for 10 min at 0⁰C and gradually heated to 60⁰C 
for 4hr. The reaction was monitored by TLC using 30% EtOAc/Hexane as the eluant. The 
reaction mixture was cooled to room temperature and basified with cold and saturated 
aqueous sodium hydroxide solution to effect precipitation. The precipitate was filtered and 




Figure 35. Preparation of pyrazole aldehyde 
 
 Initially Passerini coupling was attempted with pyrazole aldehyde 91, benzoic acid 
96 and benzyl isocyanide 94 in water at room temperature However, this reaction did not 




period of time (Figure 36).  Accordingly, we shifted our focus to converting the pyrazole 
aldehyde 91 to the corresponding acid 92 as it was presumed that the electrophilicity of the 
pyrazole aldehyde was drastically reduced because of the pyrazole ring system. 
 
 
Figure 36. Passerini reaction with pyrazole aldehyde 
 Aldehyde 91 was dissolved in pyridine: water (1:1) and KMnO4 was added to the 
reaction mixture and stirred overnight at room temperature. The reaction mixture was 
monitored by TLC using 30% EtOAc/Hexane. Upon completion, ice cold water was added 
to the reaction mixture followed by the addition of aq. NaOH to effect precipitation. The 
mixture was filtered and the filtrate was acidified with conc. HCl which resulted in the 
precipitation.  The solid was filtered and recrystallized in hexane to yield the carboxylic 
acid 92 (Figure 37).69 
 
 















As expected, the Passerini reaction was fruitful by converting pyrazole aldehyde to 
pyrazole acid.  The reaction of acid 92 with benzaldehyde 93 and benzyl isocyanide 94 
under aqueous conditions resulted in the formation of a-acetoxyamide 95a (Figure 38).  
Similarly, compounds 95b, and 95c were obtained by replacing acetophenone with 
dichloroacetophenone and benzaldehyde with p-chlorobenzaldehyde respectively (Figure 
38). 
 









































 In conclusion, we have prepared a series of azaheterocyclic compounds using 
Passerini reaction as a key step in the synthesis.  The heterocyclic motifs synthesized 
include quinoline, pyridine, and pyrazole.  The synthesized compounds were tested for 
their biological efficacy against melanoma and breast cancer cells.  While most of the 
compounds tested did not show promising cytotoxicity, these assays gave us valuable 























 All the reactants were of reagent grade, and purchased from Acros Organics, Alfa 
Aesar or Sigma Aldrich, and used without further purification. All solvents were used 
without further drying or purification and were of ACS grade purchased from Fisher 
Scientific. 
Instrumentation 
 Nuclear Magnetic Spectroscopy (NMR) spectra were produced using the Varian 
400 MHz spectrophotometer. The instrument was maintained at 25o C operating at 400 
MHz for 1H NMR, and 100 MHz for 13C NMR. The deuterated solvent (CDCl3, DMSO-
d6) used for each respective spectrum is referenced to the appropriate literature peak shift. 
Procedures 
       Method for the preparation of 2-chloroquinoline-3-carbaldehyde.70 Phosphorus 
oxychloride (6.5 mL, 70.0 mmol) was slowly added to N,N-dimethylformamide (2.3 mL, 
30.0 mmol) at 0°C and this solution was slowly added to acetanilide (1.3 g, 10.0 mmol) 
and heated at 80°C for 16h.  The reaction mixture was then poured on ice, and the white 
product was filtered and dried. The compound was purified by recrystallization from a 
petroleum ether/ ethyl acetate mixture. 
       Procedure for the preparation of 4-(bromomethyl)benzoic acid. p-Toluic acid (4.0 
g) was dissolved in 60.0 mL of EtOAc and treated with KBrO3 (14.7 g) in 50.0 mL of 
water. A solution of NaHSO3 (9.2 g) in 50.0 mL water was added dropwise over 20 




4.5-5 hrs and quenched with 100.0 mL of 1M Na2S2O3 solution.  The two layers were 
separated and the aqueous layer was extracted twice using ethyl acetate. The combined 
organic layers were dried over Na2SO4, concentrated in vacuo and recrystallized in 
methanol to yield the acid. 
       General reaction procedure for preparation of Passerini product.71,71,73 To a 
suspension of the aldehyde (1 mmol) and acid (1 mmol) in 10.0 mL water was added 
isocyanide (1.02 mmol).  The reaction mixture was sonicated and vortex stirred repeatedly 
for 30 minutes and then stirred overnight. The reaction mixture was filtered and washed 
with saturated solution of NaHCO3 followed by hexane to obtain the pure product. 
        General procedure for the amination of Passerini products. To a solution of the 
Passerini adduct (1 mmol) in DMF (6 mL), K2CO3 (20 mmol), and amine (1.2 mmol) were 
added and stirred overnight at room temperature. Ice cold water was added to the reaction 
mixture and stirred for 5 minutes. The precipitate was filtered, washed with cold water (2 













Yield: 96 %; color less solid, mp 142 – 143 °C;  1H NMR (400 MHz, DMSO-d6) δ (ppm)  
8.42 (s, 1H), 8.20 (s, 1H), 8.12 (d, J = 8.0 Hz, 1H), 7.96 – 7.99 (m, 3H), 7.86 (t, J = 7.6 Hz, 
1H), 7.68 (d, J = 8.0 Hz, 1H), 7.58 (d, J = 8.4 Hz, 2H), 6.46 (s, 1H), 4.74 (s, 2H), 1.29 (s, 
9H); 13C NMR (101 MHz, DMSO-d6) δ (ppm)  165.9, 165.1, 150.3, 147.3, 144.6, 139.4, 
132.3, 130.6, 130.4, 129.3, 129.2, 128.9, 128.5, 128.2, 127.3, 7.3.4, 51.6, 33.7, 29.0 
ESIMS: m/z calculated for C23H22BrClN2O3 (M+H)




benzoate():Yield: 55%; color less solid; mp 119 – 120  °C;  1H NMR (400 MHz, DMSO-d6) δ (ppm)   
8.39 – 8.42 (m, 1H), 8.17 – 8.21 (m, 1H), 8.10 – 8.14 (m, 1H), 7.96 – 8.01 (m, 1H), 7.91 – 7.96 (m, 
2H), 7.83 – 7.89 (m, 1H), 7.64 – 7.71 (m, 1H), 7.42 – 7.48 (m, 2H), 6.44 – 6.46 (m, 1H), 3.52 (s, 4H), 
3.50 (s, 2H), 2.32 (s, 4H), 1.29 (s, 9H); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 165.9, 165.4, 150.3, 
147.3, 145.0, 139.3, 132.3, 130.2, 129.8, 129.2, 129.1, 128.5, 128.3, 128.2, 127.3, 73.2, 66.8, 62.6, 






yl)methyl)benzoate(): Yield: 89%; color less solid; mp.140 – 145 °C; 1H NMR (400 
MHz, DMSO-d6) δ (ppm) 8.41 (s, 1H), 8.19 (s, 1H), 8.12 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 
8.4 Hz, 1H), 7.93 (d, J = 8.2 Hz, 2H), 7.84 – 7.88 (m, 1H), 7.68 (t, J = 7.5 Hz, 1H), 7.44 
(d, J = 8.2 Hz, 2H), 6.46 (s, 1H), 3.47 (s, 2H), 2.20 – 2.45 (m, 8H), 2.11 (s, 3H), 1.30 (s, 
9H); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 165.9, 165.4, 150.3, 147.3, 145.5, 139.3, 
132.2, 130.5, 130.2, 129.9, 129.7, 129.2, 129.1, 128.4, 128.2, 127.3, 73.2, 62.2, 55.3, 
53.2, 51.6, 46.4, 29.0; ESIMS: m/z calculated for C28H33ClN4O3 (M+H)




yl)methyl)benzoate(): Yield: 51%; color less solid; mp 98 – 99 °C;  1H NMR (400 MHz, 
DMSO-d6): δ (ppm) 8.41 (s, 1H), 8.19 (s, 1H), 8.12 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 8.5 
Hz, 1H), 7.93 (d, J = 7.7 Hz, 2H), 7.86 (t, J = 7.7 Hz, 1H), 7.68 (dd, J = 8.1, 7.0 Hz, 1H), 




1.92 (t, J = 10.8 Hz, 2H), 1.66-1.56 (m, 2H), 1.29 (s, 9H), 1.13 – 1.24 (m, 3H); ESIMS: 
m/z calculated for C28H33ClN4O3 (M+H)




benzoate():Yield: 68%; color less solid; mp 103 – 108  °C;  1H NMR (400 MHz, 
Acetone-d6): δ (ppm) 8.47 (s, 1H), 8.00 (d, J = 7.8 Hz, 1H), 7.95 (d, J = 8.4 Hz, 2H), 7.89 
(d, J = 8.2 Hz, 1H), 7.77 (m, 1H), 7.57 – 7.62 (m, 1H), 7.40 (d, J = 8.4 Hz, 2H), 7.32 (s, 
1H), 6.49 (s, 1H), 3.58 (s, 2H), 1.95 (m, 4H), 1.61 – 1.67 (m, 4H), 1.30 (s, 9H);  13C 
NMR (101 MHz, DMSO-d6): δ (ppm) 165.9, 165.4, 150.3, 147.3, 139.3, 132.3, 130.2, 
129.5, 129.1, 129.0, 128.5, 128.2, 128.1, 127.2, 73.2, 59.7, 54.1, 51.6, 28.9, 23.8; 
ESIMS: m/z calculated for C27H30ClN3O3 (M+H)




yl)methyl)benzoate(): Yield: 82%; color less solid; mp 109 – 111 °C; 1H NMR (400 MHz, 




(m, 2H), 7.85 (dd, J = 1.4, 7.0 Hz, 1H), 7.67 (dd, J = 1.1, 8.1 Hz, 1H), 7.21 (d, J = 8.2 Hz, 
1H), 7.11 (d, J = 1.2 Hz, 1H), 6.79 (d, J = 1.2 Hz, 1H), 6.45 (s, 1H), 5.24 (s, 2H), 1.28 (s, 
9H), 1.03 – 1.08 (m, 2H); 13C NMR (101 MHz, DMSO-d6): δ (ppm) 165.9, 165.2, 150.3, 
149.2, 147.3, 144.4, 139.3, 132.3, 130.7, 129.2, 128.9, 128.7, 128.5, 128.2, 127.8, 127.3, 
121.0, 51.6, 48.6, 28.9, 20.0, 12.7; ESIMS: m/z calculated for C28H29ClN4O3 (M+H)
+ 




yl)methyl)benzoate(): Yield: 88%; color less solid; mp 130 – 131 °C; 1H NMR (400 MHz, 
DMSO-d6): δ (ppm) 8.49 (d, J = 1.4 Hz, 1H), 8.41 (s, 1H), 8.20 (s, 1H), 8.11 (d, J = 9.2 
Hz, 2H), 7.96 – 8.03 (m, 4H), 7.86 (ddd, J = 1.4, 7.0, 8.5 Hz, 1H), 7.68 (ddd, J = 1.2, 7.0, 
8.1 Hz, 1H), 7.49 (d, J = 8.4 Hz, 2H), 6.46 (s, 1H), 5.40 (s, 2H), 1.29 (s, 9H); 13C NMR 
(101 MHz, DMSO-d6): δ (ppm) 165.8, 165.1, 150.3, 147.9, 147.3, 142.6, 139.3, 138.2, 
132.3, 130.8, 129.4, 129.1, 128.9, 128.9, 128.5, 128.2, 127.3, 122.3, 73.3, 51.6, 50.9, 28.9; 
ESIMS: m/z calculated for C26H24ClN5O5 (M+H)









imidazol-1-yl)methyl)benzoate(): Yield: 87%; color less solid; mp 143 – 144 °C; 1H NMR 
(400 MHz, DMSO-d6): δ (ppm) 8.44 (s, 1H), 8.40 (s, 1H), 8.20 (s, 1H), 8.10 (d, J = 8.2 Hz, 
1H), 7.99 (m, 3H), 7.85 (t, J = 8.2 Hz, 1H), 7.67 (t, J = 7.5 Hz, 1H), 7.37 (d, J = 8.2 Hz, 
2H), 6.48 (s, 1H), 5.40 (s, 2H), 2.23 (s, 3H), 1.28 (s, 9H); 13C NMR (101 MHz, DMSO-
d6): δ (ppm) 165.9, 165.2, 150.3, 147.3, 146.2, 145.9, 142.2, 139.4, 132.3, 130.9, 129.2, 
129.2, 128.9, 128.5, 128.4, 128.2, 127.3, 123.4, 73.3, 51.6, 50.0, 28.9, 13.4; ESIMS: m/z 
calculated for C27H26ClN5O5 (M+H)
+ 536.17 found 535.80. 
 
 
tert-Butyl 4-(4-((2-(tert-butylamino)-1-(2-chloroquinolin-3-yl)-2-oxoethoxy) carbonyl) 
benzyl) piperazine-1-carboxylate ( ): Yield: 89%; color less solid; mp 105 – 107 °C;  1H 
NMR (400 MHz, DMSO-d6): δ (ppm) 8.40 (s, 1H), 8.19 (s, 1H), 8.11 (d, J = 8.2 Hz, 1H), 
7.98 (d, J = 8.8 Hz, 1H), 7.94 (d, J = 8.0 Hz, 2H), 7.85 (t, J = 8.0 Hz, 1H), 7.67 (t, J = 7.6 
Hz, 1H), 7.44 (d, J = 7.6 Hz, 2H), 6.46 (s, 1H), 3.52 (s, 2H), 3.27 (m, 4H), 2.28 (m, 4H), 




150.3, 147.3, 145.1, 139.4, 132.3, 130.2, 129.8, 129.2, 129.1, 128.5, 128.3, 128.2, 127.3, 
79.4, 73.2, 62.1, 53.0, 51.6, 29.0, 28.7; IR (KBr): 2950, 1725, 1710, 1450 cm-1; ESIMS: 
m/z calculated for C32H39ClN4O5 (M+H)




yl)methyl)benzoate(): Yield: 70%; color less solid; mp 104 – 106 °C;  1H NMR (400 
MHz, DMSO-d6) δ (ppm) 8.68 (d, J = 1.2 Hz, 1H), 8.41 (s, 1H), 8.20 (s, 1H), 8.11 (d, J = 
8.1 Hz, 1H), 7.90  – 7.98 (m, 3H), 7.85 (d, J = 1.5 Hz, 1H), 7.67 (d, J = 1.2 Hz, 1H), 7.40 
– 7.36 (m, 2H), 6.45 (s, 1H), 5.51 (s, 2H), 1.29 (s, 9H); 13C NMR (101 MHz, DMSO-d6): 
δ (ppm) 165.9, 165.2, 152.6, 150.3, 147.3, 145.2, 142.8, 139.3, 132.3, 130.6, 129.2, 
128.9, 128.8, 128.5, 128.2, 127.3, 73.3, 52.3, 51.6, 28.9; ESIMS: m/z calculated for 
C25H24ClN5O3 (M+H)




Yield: 98 %; color less solid; mp 153 – 155  °C;  1H NMR (400 MHz, DMSO-d6) δ 




Hz, 1H), 7.04 (dd, J = 1.8, 8.0 Hz, 1H), 6.94 (s, 1H),  6.03 (d, J = 1.3 Hz, 2H), 5.92 (s, 
1H), 4.75 (s, 2H), 1.20 (s, 9H); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 167.8, 165.2, 
148.1, 147.9, 144.3, 130.5, 130.4, 130.4, 130.3, 129.7, 121.9, 108.8, 108.3, 101.9, 76.0, 
51.2, 51.1, 33.8, 29.0; ESIMS: m/z calculated for C21H22BrNO5 (M+H)




  1-(benzo[d][1,3]dioxol-5-yl)-2-(tert-butylamino)-2-oxoethyl 4-
(morpholinomethyl)benzoate (): Yield: 92%; color less solid; mp 178 – 180 °C; 1H NMR 
(400 MHz, DMSO-d6): δ (ppm) 7.94 (d, J = 8.2 Hz, 2H), 7.87 (s, 1H), 7.46 (d, J = 8.2 Hz, 
2H), 7.09 (s, 1H), 7.04 (dd, J = 8.0, 1.6 Hz, 1H), 6.93 (d, J = 8.0 Hz, 1H), 6.02 (s, 1H), 
5.92 (s, 1H), 3.53 – 3.58 (m, 4H), 3.52 (s, 2H), 2.35 (m, 4H), 1.19 (s, 9H); 13C NMR (101 
MHz, DMSO-d6): δ (ppm) 167.8, 165.5, 148.1, 147.9, 144.7, 130.6, 130.0, 129.7, 128.8, 
121.9, 108.8, 108.2, 101.9, 75.8, 66.8, 62.6, 53.8, 51.0, 29.0; ESIMS: m/z calculated for 
C25H30N2O6 (M+H)












yl)methyl)benzoate(): Yield: 78%; color less solid; mp 92 – 93 °C; 1H NMR (400 MHz, 
DMSO-d6): δ (ppm) 7.93 (d, J = 8.0 Hz, 2H), 7.86 (s, 1H), 7.44 (d, J = 8.1 Hz, 2H), 7.08 
(s, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.92 (d, J = 8.0 Hz, 2H), 6.02 (s, 2H), 5.92 (s, 1H), 3.50 
(s, 2H), 2.17 – 2.43 (m, 8H), 2.12 (s, 3H), 1.19 (s, 9H); 13C NMR (101 MHz, DMSO-d6): 
δ (ppm) 167.8, 165.5, 148.0, 147.9, 145.2, 130.5, 130.0, 129.6, 128.7, 121.9, 108.8, 108.2, 
101.9, 75.8, 62.2, 55.3, 53.2, 51.1, 46.4, 29.0; ESIMS: m/z calculated for C26H33N3O5 




yl)methyl)benzoate(): Yield: 54%; color less solid; mp 92 – 94 °C;  1H NMR (400 MHz, 
DMSO-d6): δ (ppm) 8.02 (d, J = 5.8 Hz, 1H), 7.83 – 7.97 (m, 2H), 7.42 (t, J = 6.7 Hz, 1H), 
7.00 – 7.12 (m, 2H), 6.89 – 6.95 (m, 1H), 6.02 (d, J = 5.2 Hz, 1H), 5.91 (d, J = 5.6 Hz, 
1H), 5.42 (d, J = 5.8 Hz, 0H), 3.76 (s, 0H), 3.48 (d, J = 5.2 Hz, 1H), 2.67 (d, J = 11.2 Hz, 
1H), 1.92 (s, 1H), 1.62 (d, J = 13.1 Hz, 2H), 1.19 (s, 9H); 13C NMR (101 MHz, DMSO-




108.8, 108.2, 101.9, 75.8, 62.4, 52.7, 51.1, 35.9, 29.0; ESIMS: m/z calculated for 
C26H33N3O5 (M+H)




yl)methyl)benzoate(): Yield: 67%; color less solid; mp 83 – 84 °C;  1H NMR (400 MHz, 
DMSO-d6): δ (ppm) 7.96 (d, J = 7.2 Hz, 2H), 7.85 (s, 1H), 7.75 (s, 1H), 7.34 (d, J = 7.6 
Hz, 2H), 7.16 (s, 1H), 7.08 (s, 1H), 7.03 (d, J = 8.0 Hz, 1H), 6.89 – 6.93 (m, 2H), 6.02 (s, 
2H), 5.91 (s, 1H), 5.29 (s, 2H), 1.19 (s, 9H); 13C NMR (101 MHz, DMSO-d6): δ (ppm) 
167.8, 165.3, 148.1, 147.9, 144.1, 138.3, 130.5, 130.4, 129.6, 129.3, 128.3, 121.9, 120.3, 
108.8, 108.2, 101.9, 75.9, 51.1, 49.7, 29.0; ESIMS: m/z calculated for C24H25N3O5 (M+H)
+ 




yl)methyl)benzoate(): Yield: 50%; color less solid; mp 120 – 121 °C; 1H NMR (400 MHz, 
DMSO-d6): δ (ppm) 8.68 (d, J = 1.9 Hz, 1H), 7.95 – 8.01 (m, 2H), 7.86 (d, J = 5.2 Hz, 1H), 




= 1.7, 4.4, 8.0 Hz, 1H), 6.93 (d, J = 2.4 Hz, 1H), 6.91 (d, J = 2.5 Hz, 1H), 6.02 (d, J = 1.2 
Hz, 2H), 5.92 (d, J = 5.4 Hz, 1H), 5.52 (s, 1H), 5.43 (d, J = 5.4 Hz, 1H), 1.19 (s, 9H); 13C 
NMR (101 MHz, DMSO-d6): δ (ppm) 167.8, 152.6, 148.1, 147.9, 145.2, 142.5, 130.4, 
129.5, 128.7, 121.9, 108.8, 108.2, 108.2, 101.9, 75.9, 52.3, 51.1, 29.0; ESIMS: m/z 
calculated for C23H24N4O5 (M+H)




Yield: 92 %, color less solid, mp 138 – 140 °C;  1H NMR (400 MHz, DMSO-d6) δ (ppm) 
8.44 (dd, J = 4.8, 1.9 Hz, 1H), 8.16 (s, 1H), 7.93 – 7.96 (m, 2H), 7.86 (dd, J = 1.9, 7.7 Hz, 
1H), 7.57 – 7.61 (m, 2H), 7.51 (dd, J = 4.8, 7.7 Hz, 1H), 6.31 (s, 1H), 4.75 (s, 2H), 1.27 (s, 
9H); 13C NMR (101 MHz, DMSO-d6) δ (ppm)  165.7, 165.0, 151.0, 150.5, 144.6, 139.2, 
131.4, 130.6, 130.4, 129.2, 124.2, 73.2, 51.6, 33.7, 28.9; ESIMS: m/z calculated for 
C19H20BrClN2O3 (M+H)







oate: Yield: 80 %; color less solid; mp 78 – 80  °C;  1H NMR (400 MHz, DMSO-d6) δ 
(ppm) 8.43 (dq, J = 2.4, 4.4 Hz, 1H), 8.15 (d, J = 1.9 Hz, 1H), 7.91 (dt, J = 2.1, 8.8 Hz, 
2H), 7.86 (dt, J = 1.8, 7.7 Hz, 1H), 7.50 (ddd, J = 2.0, 4.6, 7.5 Hz, 1H), 7.45 (d, J = 8.3 Hz, 
2H), 6.31 (d, J = 1.2 Hz, 1H), 3.53 (dd, J = 6.3, 11.0 Hz, 6H), 2.33 (d, J = 4.7 Hz, 4H), 
1.27 (d, J = 2.2 Hz, 10H);  13C NMR (101 MHz, DMSO-d6) δ (ppm) 167.8, 165.5, 148.1, 
147.9, 144.7, 130.5, 130.1, 129.7, 128.8, 121.9, 108.8, 108.2, 101.9, 75.8, 66.8, 62.6, 53.8, 
51.1, 29.0; ESIMS: m/z calculated for C23H28ClN3O4 (M+H)




thyl)benzoate: Yield: 71 %; color less solid; mp 99 – 100  °C;  13C NMR (101 MHz, 
DMSO-d6): δ (ppm)  165.9, 165.4, 150.9, 150.5, 145.3, 139.2, 131.4, 130.1, 129.9, 128.0, 
124.3, 72.9, 62.1, 54.9, 52.8, 51.6, 46.0, 28.9; ESIMS: m/z calculated for 
C24H31ClN4O3(M+H)







yl)methyl)benzoate: Yield: 59%; color less solid, mp 113 – 115  °C;  1H NMR (400 MHz, 
DMSO-d6) δ (ppm)   8.43 (dd, J = 1.9, 4.8 Hz, 1H), 8.15 (s, 1H), 7.88 – 7.92 (m, 1H), 7.85 
(dd, J = 1.9, 7.8 Hz, 1H), 7.50 (dd, J = 4.7, 7.7 Hz, 1H), 7.42 (d, J = 8.1 Hz, 1H), 6.30 (s, 
1H), 3.48 (s, 1H), 2.69 (d, J = 11.4 Hz, 1H), 1.89 – 1.97 (m, 1H), 1.67 (d, J = 12.5 Hz, 2H), 
1.26 (s, 9H); 13C NMR (101 MHz, DMSO-d6): δ (ppm) 165.9, 165.4, 150.9, 150.5, 145.3, 
139.2, 131.4, 130.1, 129.9, 128.0, 124.3, 72.9, 62.1, 55.0, 52.8, 51.6, 46.0, 28.9. ESIMS: 
m/z calculated for C24H31ClN4O3(M+H)




yl)methyl)benzoate (): Yield: 77%; color less solid; mp 103 – 104 °C;  1H NMR (400 MHz, 
DMSO-d6) δ (ppm) 8.41 (d, J = 5.6 Hz, 1H), 8.20 (d, J = 5.7 Hz, 1H), 8.11 (dd, J = 1.8, 
8.3 Hz, 1H), 7.99 – 8.04 (m, 2H), 7.86 (dt, J = 5.5, 8.4 Hz, 1H), 7.67 (t, J = 7.6 Hz, 1H), 
7.63 – 7.57 (m, 2H), 7.34 (td, J = 6.3, 5.8, 2.8 Hz, 1H), 6.47 (s, 1H), 5.42 (d, J = 6.0 Hz, 
2H), 1.29 (s, 8H). ESIMS: m/z calculated for C22H23ClN4O3 (M+H)









yl)methyl)benzoate (): Yield: 76 %; color less solid; mp 95 – 97  °C;  1H NMR (400 MHz, 
DMSO-d6) δ (ppm) 8.67 (s, 1H), 8.43 (dd, J = 1.8, 4.7 Hz, 1H), 8.15 (s, 1H), 7.98 (s, 1H), 
7.94 (d, J = 8.2 Hz, 2H), 7.85 (dd, J = 1.8, 7.6 Hz, 1H), 7.50 (dd, J = 4.8, 7.6 Hz, 1H), 7.38 
(d, J = 8.3 Hz, 2H), 6.29 (s, 1H), 5.51 (s, 2H), 1.26 (s, 9H). ESIMS: m/z calculated for 
C21H22ClN5O3 (M+H)




1,1-dimethylpiperazin-1-ium iodide():Yield: 80%; color less solid; 1H NMR (400 MHz, 
Chloroform-d) δ (ppm)  8.45 (s, 1H), 8.05 (d, J = 7.9 Hz, 1H), 8.02 – 7.94 (m, 0H), 7.90 
(d, J = 8.0 Hz, 1H), 7.74 (t, J = 7.9 Hz, 1H), 7.56 (q, J = 9.8, 8.6 Hz, 1H), 7.47 – 7.40 (m, 










1,1-dimethylpiperazin-1-ium iodide: Yield: 80%; color less solid; 1H NMR (400 MHz, 
CDCl3): δ (ppm) 8.01 (d, J = 7.0 Hz, 2H), 7.43 (d, J = 7.3 Hz, 2H), 6.95 – 7.01 (m, 2H), 
6.80 (dd, J = 1.5, 8.4 Hz, 1H), 6.08 (s, 1H), 5.95 (s, 2H), 3.75 (s, 2H), 3.71 (m, 4H), 3.54 
(s, 6H), 2.85 (m, 4H), 1.35 (s, 9H); 13C NMR (101 MHz, CDCl3): δ (ppm) 167.7, 165.0, 
148.3, 148.1, 143.0, 130.2, 129.7, 129.3, 128.8, 121.9, 108.6, 107.9, 101.7, 75.9, 68.1, 62.5, 
60.9, 51.9, 46.5, 28.9; ESIMS: m/z calculated for C27H36IN3O5 (M+H)
+ 610.18 found 
482.30. 
        Preparation of N-phenyl-N’-(1-phenylethylidene)-hydrazine.74 Phenyl hydrazine 
hydrochloride (2.0 g, 13.8 mmol) was added to a solution of acetophenone (1.8 g, 15.2 
mmol) in 50.0 mL of ethanol at 0⁰C followed by the slow addition of glacial acetic acid 
(1.5 mL). The reaction mixture was then refluxed for 2hr. The completion of the reaction 
mixture was checked by TLC using 10% EtOAc/hexane. The reaction mixture was cooled 
to room temperature to effect precipitation. The product was filtered, washed with cold 
ethanol (2 x 10.0 mL) and dried under vaccum to obtain pure acetophenone 
phenylhydrazone as a yellow solid (2.8 g, 90% yield). 
         Preparation of 1,3-diphenyl-1H-pyrazole-4-carboxaldehyde.75 Phosphoryl 
chloride (1.0  mL, 11.4 mmol) was added to N,N-dimethylformamide (0.8  mL, 11.4 mmol) 




acetophenone phenylhydrazone (2.0 g, 9.5 mmol) in DMF (5.0 mL) and the reaction 
mixture was allowed to stir for 10 minutes and gradually heated to 60⁰C for 4hr. The 
reaction was monitored by TLC using 30% EtOAc/hexane. The reaction mixture was 
cooled to room temperature and basified with cold and saturated aqueous sodium 
hydroxide solution (pH ~8.0) to cause precipitation. The solid was filtered and washed with 
cold water (2 x 20.0 mL) to obtain the crude product as a off white solid (2.2 g, 92% yield) 
            Preparation of the aryl-1-phenylpyrazole-4-carboxylic acid. Aldehyde (1 
mmol) was dissolved in 50 mL (pyridine: water =1:1) and KMnO4 (1 mmol) was added.  
The reaction was stirred overnight at room temperature. The completion of reaction was 
monitored by TLC using 30% EtOAc/hexane. Upon completion, ice cold water was added 
to the reaction mixture followed by the addition of aq. NaOH to effect precipitation. The 
mixture was filtered and the filtrate was acidified with conc. HCl which resulted in the 




1,3-diphenyl-1H-pyrazole-4-carboxylic acid: 1H NMR (400 MHz, DMSO-d6): δ (ppm) 
12.55 (s, 1H), 9.06 (d, J = 2.1 Hz, 1H), 7.93 – 7.98 (m, 3H), 7.80 (dt, J = 2.1, 7.71 Hz, 2H), 






2-(benzylamino)-2-oxo-1-phenylethyl 1,3-diphenyl-1H-pyrazole-4-carboxylate:  1H 
NMR (400 MHz, DMSO-d6): δ (ppm) 9.28 (s, 1H), 8.76 – 8.85 (m, 1H), 7.99 (d, J = 7.8 
Hz, 2H), 7.81 (d, J = 3.9 Hz, 2H), 7.49 – 7.58 (m, 5H), 7.39 (dd, J = 9.9, 18.5 Hz, 9H), 




4-carboxylate: 1H NMR (400 MHz, DMSO-d6): δ (ppm) 9.32 (s, 1H), 8.98 (t, J = 5.9 Hz, 
1H), 7.99 (d, J = 8.4 Hz, 2H), 7.74 – 7.81 (m, 2H), 7.68 (d, J = 1.0 Hz, 1H), 7.50 – 7.58 
(m, 3H), 7.34 – 7.47 (m, 6H), 7.19 – 7.31 (m, 6H), 6.46 (s, 1H), 6.46 (s, 1H), 4.36 (dd, J = 
3.0, 5.3 Hz, 2H); 13C NMR (101 MHz, DMSO-d6): δ (ppm) 167.2, 161.5, 153.7, 139.4, 
139.1, 134.8, 134.7, 134.7, 133.4, 132.0, 131.2, 130.1, 129.5, 129.4, 129.1, 128.7, 128.3, 






carboxylate: Yield: 49%; color less solid; 1H NMR (400 MHz, Chloroform-d) δ (ppm)   
8.55 (d, J = 1.5 Hz, 1H), 7.73 (d, J = 7.9 Hz, 2H), 7.64 (dd, J = 5.3, 2.5 Hz, 2H), 7.49 (t, J 
= 7.5 Hz, 2H), 7.38 (d, J = 1.5 Hz, 0H), 7.36 – 7.28 (m, 11H), 7.26 (d, J = 1.4 Hz, 1H), 
6.21 (s, 1H), 5.95 (d, J = 6.2 Hz, 1H), 4.28 (d, J = 6.0 Hz, 2H). 13C NMR (101 MHz, 
CDCl3) δ (ppm) 168.07, 161.09, 154.05, 139.14, 137.88, 135.17, 134.60, 133.23, 132.85, 
129.89, 129.83, 129.65, 129.27, 129.16, 129.09, 129.06, 128.88, 128.46, 128.16, 127.80, 
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